Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091), a China-based pharmaceutical company, has announced that clinical data for its paclitaxel polymer micelles will be presented at the prestigious American Society of Clinical Oncology (ASCO) annual meeting.
Clinical Data from Retrospective Study in NSCLC Treatment
The data originates from a retrospective study examining the real-world clinical practice of paclitaxel micelles in combination with immunotherapy for the first-line treatment of advanced squamous non-small cell lung cancer (NSCLC). A total of 45 patients with a median age of 68 years received the protocol treatment, which included 3 patients with baseline brain metastasis. The paclitaxel micelle administration was dosed at 230 mg/m² weekly. The study demonstrated an overall objective response rate (ORR) of 84.4% and a disease control rate (DCR) of 100% among the treated patients. Notably, patients with PD-L1 expression less than 1% had an ORR of 80%, and those with PD-L1 expression between 1% and 49% had an ORR of 90%. Progression-free survival (PFS) and overall survival (OS) data are yet to mature, but a 6-month PFS of 94.8% was indicated by Kaplan Meier survival analysis. These results suggest that the combination regimen has promising efficacy and safety profiles, warranting further exploration in first-line treatment settings.
Paclitaxel Micelles: A Novel Drug Delivery System
Paclitaxel micelles represent a novel dosage form of the broad-spectrum chemotherapy agent paclitaxel, known for its exceptional in vivo stability and heightened sensitivity to drug release within tumor environments. This formulation offers relatively improved safety even at significantly increased clinical dosages. The product received market approval in October 2021 for the first-line treatment of locally advanced or metastatic NSCLC with negative epidermal growth factor receptor (EGFR) and negative anaplastic lymphoma kinase (ALK), which cannot be surgically removed, in combination with platinum-based chemotherapy.-Fineline Info & Tech
